AI assistant
PFIZER INC — Director's Dealing 2020
Mar 3, 2020
29831_dirs_2020-03-03_0117219d-d980-4a54-80e4-77dc81ab6348.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2020-02-28
Reporting Person: DAMELIO FRANK A (Executive Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-02-28 | Common Stock | M | 173675.0000 | $27.3700 | Acquired | 556084.0000 | Direct |
| 2020-02-28 | Common Stock | F | 41113.0000 | $33.4200 | Disposed | 514971.0000 | Direct |
| 2020-02-28 | Common Stock | F | 89721.0000 | $36.4500 | Disposed | 425250.0000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-02-28 | Stock Appreciation Rights | $27.3700 | M | 173675.0000 | Disposed | 2020-02-28 | Common Stock (173675.0000) | Direct |
Footnotes
F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F4: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.